NCT04456595已完成3 期
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 12,688
- 试验地点
- 32
- 主要终点
- Frequency of adverse events up to seven days after immunization
研究概览
简要总结
This is a phase III clinical trial to assess efficacy and safety of the Adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac in health care professionals
详细描述
This is a phase III clinical trial to assess efficacy and safety of the Adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac in health care professionals.
The study will be double-blind placebo-controlled trial with participants randomly allocated 1:1 to placebo and vaccine arms.
The immunization schedule is two doses intramuscular injections (deltoid) with a 14-days interval.
For efficacy, the study aims to detect COVID-19 cases, defined as symptomatic SARS-CoV-2 infections, after the second week post-immunization schedule.
For safety and immunogenicity, participants are categorized in two age groups, Adults (18-59 years) and Elderly (60 years and above). Safety database aims to detect adverse reactions with frequency of 1:1000 or higher in adults and 1:500 in elderly.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adults 18 years of age or older;
- •Healthcare professionals who work in direct contact care of people with possible or confirmed COVID-19 cases;
- •Agree with periodic contacts by phone or electronic means, and home visits;
- •Show voluntary intention to participate in the study, documented by the informed consent form signed by participant.
排除标准
- •For females: Pregnancy (confirmed by positive beta-hCG test), breastfeeding or intent to engage in sexual relations with reproductive intent without use of birth control methods in the three months following vaccination;
- •Evidence of uncontrolled neurological, cardiac, pulmonary, hepatic or renal disease, according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;
- •Diseases with impaired immune system including: neoplasms (except basal cell carcinoma), congenital or acquired immunodeficiencies and autoimmune diseases not controlled according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;
- •Behavioral, cognitive or psychiatric disease that, in the opinion of the principal investigator or his or her representative physician, affects the participant's ability to understand and cooperate with all study protocol requirements;
- •Any alcohol or drug abuse over the 12 months prior to enrollment in the study that has caused medical, professional or family problems, indicated by clinical history;
- •History of severe allergic reactions or anaphylaxis to the study vaccine or to components thereof;
- •History of asplenia;
- •Participation in another clinical trial with an investigational product in the six months prior to enrollment in the study or planned participation in another clinical trial within the two years following enrollment;
- •Previous participation in a study to evaluate a COVID-19 vaccine or prior exposure to a COVID-19 vaccine;
- •Use of immunosuppressant therapy regimens within the six months prior to enrollment in the study for planned use within the two years following enrollment. Immunosuppressant therapy regimens include: antineoplastic chemotherapy, radiation therapy and immunosuppressants to induce transplant tolerance, among others.
- •Use of immunosuppressive doses of corticosteroids within the three months prior to the enrollment in the study and planned use of immunosuppressive doses of corticoids within the three months following enrollment in the study. Immunosuppressive doses of corticosteroids will be considered the equivalent prednisone 20 mg/day for adults, for longer than one week. Continued use of topical or nasal corticosteroids is not considered an immunosuppressant;
- •Received blood products (transfusions or immunoglobulins) within the three months prior to enrollment in the study, or planned administration of blood products or immunoglobulins within the two years following enrollment in the study;
- •Suspected or confirmed fever within the 72 hours prior to vaccination or axillary temperature greater than 37.8 °C* on the day of vaccination (enrollment may be postponed until participant has gone 72 hours without fever);
- •Possible or confirmed case of COVID-19 on the day of vaccination (vaccination can be postponed until the participant completes 72 hours without symptoms or the diagnosis is ruled out);
- •Received live attenuated virus vaccine or inactivated vaccine within the 28 days or 14 days, respectively, prior to enrollment in the study, or immunization planned within the 28 days after enrollment in the study;
- •History of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture
- •Any other condition that, in the opinion of the principal investigator or his/her representative physician, could put the safety/rights of potential participants at risk or prevent them from complying with this protocol.
结局指标
主要结局
Frequency of adverse events up to seven days after immunization
时间窗: Seven days after each immunization
Frequency of adverse reaction in the seven days following each immunization per age group
Incidence of COVID-19 cases after two-doses immunization schedule
时间窗: Two weeks after second dose up to one year after first dose
Number of virologically-confirmed symptomatic COVID-19 two weeks after second dose of vaccine
次要结局
- Frequency of severe COVID-19 cases(From first vaccination up to one year after first dose)
- Seroconversion rate(Two weeks after each vaccination)
- Combined incidence of SARS-CoV-2 infection(Two weeks after second dose up to one year after first dose)
- Frequency of adverse events up to 28 days after immunization(28 days after each immunization)
- Incidence of COVID-19 cases after two-doses immunization schedule according to previous exposure(Two weeks after first dose up to one year after first dose)
- Incidence of COVID-19 cases after 14-days of first immunization(Two weeks after last dose uup to one year after first dose)
- Incidence of severe COVID-19 cases after two-doses immunization schedule(Two weeks after second dose up to one year after first dose)
- Frequency of adverse events of special interest after immunization(From first vaccination up to one year after first dose)
- Cell-mediated immune profile(Two and four weeks afer each vaccination)
- Seropositivity rate(Two weeks after second vaccination)
研究者
研究点 (32)
Loading locations...
相似试验
已完成
2 期
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 InfectionCOVID-19NCT05047601Pfizer2,954
已完成
2 期
A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African AdultsSARS-CoV-2 InfectionCOVID-19NCT04533399Novavax4,422
已完成
3 期
Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated VaccineSARS-CoV2 InfectionNCT04508075PT Bio Farma1,620
已完成
3 期
PH94B Nasal Spray for Anxiety Induced by a Public Speaking ChallengeSocial Anxiety DisorderNCT04754802VistaGen Therapeutics, Inc.224
已完成
3 期
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United KingdomSARS-CoV-2 InfectionCOVID-19NCT04583995Novavax15,185